GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » ROE % Adjusted to Book Value

Gyre Therapeutics (Gyre Therapeutics) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics ROE % Adjusted to Book Value?

Gyre Therapeutics's ROE % for the quarter that ended in Dec. 2023 was -696.28%. Gyre Therapeutics's PB Ratio for the quarter that ended in Dec. 2023 was N/A. Gyre Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was N/A.

Gyre Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Gyre Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics ROE % Adjusted to Book Value Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
- - -

Gyre Therapeutics Semi-Annual Data
Dec21 Dec22 Dec23
ROE % Adjusted to Book Value - - -

Competitive Comparison of Gyre Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Gyre Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gyre Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's ROE % Adjusted to Book Value falls into.


Gyre Therapeutics ROE % Adjusted to Book Value Calculation

Gyre Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-696.28% / N/A
=N/A

Gyre Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-696.28% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gyre Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics (Gyre Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
Traded in Other Exchanges
L9S:Germany
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Website
https://www.gyretx.com
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines

From GuruFocus

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

By PRNewswire • 12-15-2023